Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
3.43
Dollar change
+0.10
Percentage change
2.84
%
Index- P/E- EPS (ttm)-5.09 Insider Own28.25% Shs Outstand7.44M Perf Week2.54%
Market Cap32.29M Forward P/E- EPS next Y-1.12 Insider Trans34.20% Shs Float6.74M Perf Month38.51%
Income-38.77M PEG- EPS next Q-0.35 Inst Own6.09% Short Float0.17% Perf Quarter67.56%
Sales0.00M P/S- EPS this Y74.74% Inst Trans- Short Ratio0.40 Perf Half Y65.35%
Book/sh6.88 P/B0.50 EPS next Y22.22% ROA-40.18% Short Interest0.01M Perf Year12.10%
Cash/sh2.67 P/C1.29 EPS next 5Y- ROE-48.05% 52W Range1.72 - 3.84 Perf YTD18.86%
Dividend Est.- P/FCF- EPS past 5Y34.13% ROI-59.95% 52W High-10.55% Beta1.49
Dividend TTM- Quick Ratio15.19 Sales past 5Y-20.00% Gross Margin- 52W Low99.71% ATR (14)0.21
Dividend Ex-Date- Current Ratio15.19 EPS Y/Y TTM-118.81% Oper. Margin0.00% RSI (14)68.31 Volatility4.28% 7.39%
Employees- Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q60.27% Payout- Rel Volume0.40 Prev Close3.34
Sales Surprise- EPS Surprise8.70% Sales Q/Q- EarningsFeb 12 BMO Avg Volume28.42K Price3.43
SMA2019.79% SMA5028.41% SMA20033.46% Trades Volume11,360 Change2.84%
Date Action Analyst Rating Change Price Target Change
Sep-01-20Downgrade Oppenheimer Outperform → Perform
Jul-06-20Upgrade B. Riley FBR Neutral → Buy $2
Jan-13-20Downgrade B. Riley FBR Buy → Neutral
Aug-29-19Initiated B. Riley FBR Buy $7.75
Jul-18-19Initiated Oppenheimer Outperform $7
Jun-26-19Initiated H.C. Wainwright Buy $6
Feb-12-24 08:00AM
07:57AM
Feb-01-24 08:00AM
Dec-13-23 08:00AM
Nov-13-23 08:20AM
08:00AM Loading…
08:00AM
Oct-23-23 08:00AM
Oct-04-23 08:00AM
Sep-26-23 08:00AM
Sep-06-23 08:00AM
Aug-23-23 03:49AM
Aug-22-23 09:19AM
Aug-11-23 07:10AM
07:00AM
Aug-09-23 04:05PM
08:02AM Loading…
Jul-28-23 08:02AM
Jul-10-23 09:00AM
Jul-07-23 08:00AM
Jul-05-23 09:00AM
Jun-23-23 07:00AM
Jun-22-23 09:00AM
May-17-23 09:00AM
May-10-23 07:41AM
May-08-23 07:00AM
Apr-04-23 08:01AM
08:00AM
Mar-30-23 08:30AM
06:57AM
Mar-13-23 08:00AM
Mar-08-23 09:00AM
08:28AM Loading…
Mar-04-23 08:28AM
Feb-28-23 01:00PM
09:40AM
Feb-15-23 04:02PM
Feb-14-23 07:00AM
Feb-07-23 09:00AM
Jan-25-23 09:00AM
Jan-24-23 04:15PM
Jan-17-23 10:00AM
08:45AM
Jan-13-23 09:00AM
Jan-05-23 09:00AM
Dec-29-22 06:02AM
Dec-28-22 08:00AM
Dec-22-22 08:00AM
Nov-14-22 07:00AM
Nov-09-22 04:15PM
Nov-07-22 04:15PM
Sep-30-22 09:00AM
Sep-29-22 09:00AM
Sep-21-22 08:45AM
Sep-14-22 04:15PM
Sep-13-22 08:00AM
Sep-12-22 09:00AM
Aug-11-22 01:00PM
07:00AM
Aug-02-22 04:15PM
Jul-27-22 08:00AM
Jul-07-22 08:55AM
Jun-22-22 06:10PM
Jun-21-22 08:00AM
Jun-16-22 04:15PM
Jun-14-22 08:00AM
May-23-22 04:15PM
May-18-22 11:20AM
07:30AM
May-16-22 01:30PM
01:20PM
May-12-22 08:00AM
May-06-22 09:02AM
Apr-25-22 08:30AM
Mar-25-22 07:30AM
Mar-22-22 07:30AM
Mar-09-22 08:30AM
Feb-28-22 08:30AM
Feb-23-22 09:50AM
Feb-22-22 09:09AM
Feb-14-22 07:00AM
Feb-07-22 08:30AM
Jan-03-22 08:30AM
Dec-23-21 10:49AM
Dec-22-21 03:40PM
07:28AM
Dec-21-21 04:57AM
Dec-02-21 07:00AM
Nov-24-21 08:30AM
Nov-12-21 05:34PM
Nov-11-21 08:30AM
Nov-10-21 07:00AM
Nov-04-21 08:30AM
Oct-07-21 10:15AM
Oct-06-21 08:30AM
Sep-27-21 08:30AM
Sep-22-21 08:30AM
Sep-14-21 08:30AM
Sep-08-21 08:30AM
Aug-31-21 02:27PM
Aug-27-21 08:40AM
Aug-25-21 07:02AM
Aug-12-21 07:00AM
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kavuru VimalDirectorSep 25Buy1.85676,3711,249,9341,188,076Sep 27 07:46 PM
Olds DonaldDirectorAug 31Buy2.05381781381Sep 05 03:54 PM